BioSpace News Archive

Renowned Stanford University specialist joins Hoag to bring care for Marfan Syndrome and Related Conditions to the Jeffrey M. Carlton Heart & Vascular Institute

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma.

Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy.

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.

A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.”

Pharmapack Europe (#PharmapackEU), announces the winners of the 2020 Pharmapack Awards. Due to the outstanding quality of entries, eight worthy winners were chosen across two categories: ‘Exhibitor Innovations’ and ‘Health Products’.

Last week, MassBio® launched a new mentoring program, MassCONNECT.DH, to support the growth and success of digital health startups in Massachusetts.

GenMark Diagnostics, Inc. announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020.

Results from a phase 2 randomized trial study published today in Annals of Internal Medicine

Collegium Pharmaceutical, Inc. announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 in a public offering registered under the Securities Act of 1933, as amended.